Comparing brimonidine 0.2% to apraclonidine 1.0% in the prevention of intraocular pressure elevation and their pupillary effects following laser peripheral iridotomy

Japanese Journal of Ophthalmology

Volumn 49, Issue 2, 2005, Pages 89-92

  Yuen, Nancy S Y ^a   Cheung, Peggy ^a   Hui, Sui Ping ^b  

^a TUNG WAH EASTERN HOSPITAL   (Hong Kong)

^b PAMELA YOUDE NETHERSOLE EASTERN HOSPITAL   (Hong Kong)

Author keywords

Apraclonidine; Brimonidine; Intraocular pressure; Laser peripheral iridotomy; Pupil

Indexed keywords

APRACLONIDINE; BRIMONIDINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INSTILLATION; FEMALE; HUMAN; INTRAOCULAR PRESSURE ABNORMALITY; IRIDOTOMY; LASER; MALE; PRIORITY JOURNAL; PUPIL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STINGING SENSATION; STUDENT T TEST;

ADRENERGIC ALPHA-AGONISTS; AGED; CLONIDINE; DOUBLE-BLIND METHOD; FEMALE; GLAUCOMA, ANGLE-CLOSURE; HUMANS; INTRAOCULAR PRESSURE; IRIDECTOMY; LASER SURGERY; MALE; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; PUPIL; QUINOXALINES;

EID: 18044391063     PISSN: 00215155     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10384-004-0149-9     Document Type: Article

References (25)

1. Moster MR, Schwartz LW, Spaeth GL, Wilson RP, McAllister JA, Poryzees EM. Laser iridectomy: a controlled study comparing argon and neodymium: YAG. Ophthalmology 1986;93:20-22.
2. Kitazawa Y, Taniguchi T, Sugiyama K. Use of apraclonidine to reduce intra-ocular pressure rise following Q-switched Nd: YAG laser iridotomy. Ophthalmic Surg Lasers 1989;20:49-52.
3. Silverstone DE, Brint SF, Olander KW, et al. Prophylactic use of apraclonidine for intraocular pressure increase after Nd: YAG capsulotomies. Am J Ophthalmol 1992;113:401-405.
4. Robin AL. Short-term effects of unilateral 1% apraclonidine therapy. Arch Ophthalmol 1988;106:912-915.
5. Lewis R, Perkins TW, Gangnon R, Kaufman PL, Heatley GA. The rarity of clinically significant rise in intraocular pressure after laser peripheral iridotomy with apraclonidine. Ophthalmology 1998;105: 2256-2259.
6. Schadlu R, Maus TL, Nau CB, Brubaker FL. Comparison of the efficacy of apraclonidine and brimonidine as aqueous suppressants in humans. Arch Ophthalmol 1998;116:1441-1444.
7. Maus TL, Nau CB, Brubaker RF. Comparison of the early effects of brimonidine and apraclonidine as topical ocular hypotensive agents. Arch Ophthalmol 1999;117:586-591.
8. Lachkar Y, Migdal C, Dhanjil S. Effect of brimonidine tartrate on ocular hemodynamic measurements. Arch Ophthalmol 1998;116: 1591-1594.
9. Schuman JS, Horwitz B, Choplin NT, David R, Albracht D, Chen K. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. Arch Ophthalmol 1997;115:847-852.
10. Kaufman PF. Assessment of ocular hypotensive mechanisms and additivity of antiglaucoma drugs in humans. Arch Ophthalmol 1999;117:673-674.
11. Mastropasqua L, Carpineto P, Ciancaglini M. Brimonidine and pupillary diameter. Ophthalmology 1998;105:1352-1353.
12. Brogliatti B, Bogetto C, Prandi B, Carenini B. Pupillographic, tonographic and refractive parameter changes after topical instillation of Brimonidine tartrate 0.2% in healthy subjects. Acta Ophthalmol Scand 1998;227(Suppl):34-35.
13. LoPresti L, Morgese A, Ravot M, Brogliatti B, Boles Carenini B. Ultrabiomicroscopic study of the effects of brimonidine, apraclonidine, latanoprost and ibopamine on the chamber angle and ciliary body. Acta Ophthalmol Scand Suppl 1998;227:32-34.
14. Marchini G, Babighian S, Tosi R, Bonomi L. Effects of 0.2% brimonidine on ocular anterior structures. J Ocul Pharmacol Ther 1999;15:337-344.
15. Chevrier RL, Assalian A, Duperre J, Lesk MR. Apraclonidine 0.5% versus brimonidine 0.2% for the control of intraocular pressure elevation following anterior segment laser procedures. Ophthalmic Surg Lasers 1999;30:199-204.
16. Barnes SD, Campagna JA, Dirks MS, Doe EA. Control of intraocular pressure elevations after argon laser trabeculoplasty: comparison of brimonidine 0.2% to apraclonidine 1.0%. Ophthalomology 1999;106:2033-2037.
17. David R, Spaeth GL, Clevenger CE, et al. Brimonidine in the prevention of introcular pressure elevation following argon laser trabeculoplasty. Arch Ophthalmol 1993;111:1387-1390.
18. Chen TC, Ang RT, Grosskreutz CL, Pasquale LR, Fan JT. Brimonidine 0.2% versus apraclonidine 0.5% for prevention of intraocular pressure elevations after anterior segment laser surgery. Ophthalmology 2001;108:1033-1038.
19. Seong GJ, Lee YG, Lee JH, et al. Effect of 0.2% brimonidine in preventing intraocular pressure elevation after Nd: YAG laser posterior capsulotomy. Ophthalmic Surg Lasers 2000;31:308-314.
20. The Brimonidine-ALT Study Group. Effect of brimonidine 0.5% on intraocular pressure spikes following 360 argon laser trabeculoplasty. Ophthalmic Surg Lasers 1995;26:404-409.
21. Nordlund JR, Pasquale LR, Robin AL, et al. The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine. Arch Ophthalmol 1995;113:77-83.
22. James Burke, Michal Schwartz. Preclinical evaluation of brimonidine. Surv Ophthalmol 1996;41(Suppl 1):S9-S18.
23. Twa MD, Bailey MD, Hayes J, Bullimore M. Estimation of pupil size by digital photography. J Cataract Refract Surg 2004;30: 381-389.
24. Berson FG, Cohen HB, Foerster RJ, Lass JH, Novack GD, Duzman E. Levobunolol compared with timolol for the long-term control of elevated intraocular pressure. Arch Ophthalmol 1985;103: 379-382.
25. Long DL, Zimmerman T, Spaeth G, Novack G, Burke PJ, Duzman E. Minimum concentration of levobunolol required to control intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol 1985;99:18-22.